WELCOME TO MEDUNIK CANADA 

Canadians living with rare diseases should have access to the best treatments available. This is precisely what we, at Médunik Canada, are dedicated to achieve.  We want to bring to Canada orphan drugs currently unavailable to Canadians.

To accomplish our mission, we are working at developing strategic partnerships with international pharmaceutical and biopharmaceutical companies that are looking at optimizing the introduction and distribution of their orphan drugs on the small-size Canadian market. Through in-licensing partnerships, Médunik Canada offers turn-key operations - ranging from regulatory approval strategy to post-approval activities - to assure the commercial success of our partners’ novel orphan treatments.

Our business strategy is based on our long-standing success in specialty and small population markets, coupled with our solid and independent financial backing, our infrastructure and our team’s dedication to medically unique populations.

Médunik Canada wants to meet the needs of a medically underserved population by becoming the missing piece of our potential partners’ global orphan drug strategy.

Éric Gervais
Executive Vice-President

Last update: April 24, 2013